Compare PayPal Holdings, Inc. (PYPL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

PayPal trades at $56.10, up 0.09% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $31.8B in 2024 to $33.2B in 2025 and net income of $5.23B. Valuation metrics appear attractive with P/E of 10.62 and EV/EBITDA of 6.89. Recent Q2 2026 earnings beat expectations at $1.38 EPS versus $1.28 expected. The company maintains robust cash flow with $1.53B net cash flow in 2025 and recently announced a Meta partnership for AI-powered checkout.

PayPal presents a compelling value opportunity with reasonable valuation and solid financials, though faces competitive pressures in digital payments. Analyst consensus is mixed with 35.7% buy ratings but a $56.41 price target suggesting limited upside. Key risks include checkout competition and slowing growth, balanced by new CEO's turnaround focus on Venmo, BNPL, and cost efficiency initiatives.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.